REC-4881
Phase 2Small molecule
REC-4881 is one of 8 small molecule programs targeting Familial adenomatous polyposis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Familial Adenomatous Polyposis
#DrugCompanyPhaseTrials
1Rocaltrol
Jazz PharmaceuticalsApproved
Actigall
AbbVieApproved
Bayer Aspirin
BayerApproved
E-Mycin
AAzurity Pharmaceuticals
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rapamycin
MMaastricht Radiation Oncology
Phase 2
Erapa
RRapamycin Holdings, Inc. dba Emtora Biosciences
Phase 3
REC-4881
RRecursion Pharmaceuticals Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for REC-4881. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRecursion Pharmaceuticals Inc.